Literature DB >> 19969447

[F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study.

T Steuber1, T Schlomm, H Heinzer, M Zacharias, S Ahyai, K F Chun, A Haese, S Klutmann, J Köllermann, G Sauter, J Mester, P Mikecz, M Fisch, H Huland, M Graefen, G Salomon.   

Abstract

PURPOSE: To evaluate the diagnostic potential of PET/CT using ([F(18)]fluorethylcholine (FEC) for lymph node (LN) staging in high risk prostate cancer (PCa) patients prior to radical prostatectomy (RP). PATIENTS AND METHODS: Twenty patients with localised PCa and > or =20% LN risk according to a published nomogram were prospectively enrolled. FEC PET/CT was done minimum 14 d after prostate biopsy. Afterwards, open RP and extended pelvic LN dissection (ePLND) were performed. Clinical stage, Prostate Specific Antigen (PSA) and biopsy Gleason Grading were assessed and histopathological evaluation of the RP-specimens and dissected LN has been performed. The results from PET/CT were compared with LN metastasis according to their anatomical site.
RESULTS: Overall, 285 LN have been removed with a mean number of 15 nodes per patient (7-26). Of the 20 patients, 9 men were LN positive (45%), which corresponds to 31 positive LN with a mean size of 7 mm (0.8-12 mm). Dissection of the obturator fossa, external iliac artery/vein and internal iliac artery/vein revealed 36%, 48% and 16% of positive LN, respectively. FEC PET/CT did not detect one single positive LN, thus was false-negative in 31 metastasis and true negative in 254 LN.
CONCLUSION: Based on our results which confirmed experience from the previous studies, FEC PET/CT scan did not prove to be useful for LN staging in localised PCa prior to treatment and should thus not be applied if clinically occult metastatic disease is suspected. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969447     DOI: 10.1016/j.ejca.2009.11.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

Review 1.  Individualized image-based lymph node irradiation for prostate cancer.

Authors:  Hanneke J M Meijer; Oscar A Debats; Emile N J Th van Lin; Marco van Vulpen; J Alfred Witjes; Wim J G Oyen; Jelle O Barentsz; Johannes H A M Kaanders
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

Review 2.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

3.  18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.

Authors:  Kirsten M Selnæs; Brage Krüger-Stokke; Mattijs Elschot; Frode Willoch; Øystein Størkersen; Elise Sandsmark; Siver A Moestue; May-Britt Tessem; Dag Halvorsen; Eirik Kjøbli; Anders Angelsen; Sverre Langørgen; Helena Bertilsson; Tone F Bathen
Journal:  Eur Radiol       Date:  2018-01-02       Impact factor: 5.315

Review 4.  PET/CT Imaging and Radioimmunotherapy of Prostate Cancer.

Authors:  Kirsten Bouchelouche; Scott T Tagawa; Stanley J Goldsmith; Baris Turkbey; Jacek Capala; Peter Choyke
Journal:  Semin Nucl Med       Date:  2011-01       Impact factor: 4.446

5.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Authors:  Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

Review 6.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

7.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.

Authors:  David Pfister; Daniel Porres; Axel Heidenreich; Isabel Heidegger; Ruth Knuechel; Florian Steib; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

8.  Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.

Authors:  Qiaohong Ouyang; Zhongxiang Duan; Jixiao Lei; Guangli Jiao
Journal:  Tumour Biol       Date:  2015-09-29

9.  ¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.

Authors:  H Kjölhede; G Ahlgren; H Almquist; F Liedberg; K Lyttkens; T Ohlsson; O Bratt
Journal:  World J Urol       Date:  2013-10-20       Impact factor: 4.226

10.  External Validation of the Briganti Nomogram to Predict Lymph Node Invasion in Prostate Cancer-Setting a New Threshold Value.

Authors:  Bartosz Małkiewicz; Kuba Ptaszkowski; Klaudia Knecht; Adam Gurwin; Karol Wilk; Paweł Kiełb; Krzysztof Dudek; Romuald Zdrojowy
Journal:  Life (Basel)       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.